In June 2014, Pfizer made public their failed
takeover bid of UK based AstraZeneca, with price being the issue according to
their CFO Frank D’Amelio. The takeover offer, valued at £55 per share, was
rejected and led to Pfizer’s share price declining by 1 percent. The
significant part of D’Amelio’s comments was that he said that the company would
be willing to take on more debt for the right deal, and that he would, if
necessary, lever up the balance sheet to get a deal done that would create
shareholder value (Pettypiece, 2014). To do so they would have to reshuffle
their capital structure to identify their optimal capital structure. The
optimal capital structure only exists when a certain mixture of capital used by
the firm leads to maximising the company value (Culp, 2002: p72).
Effectively
what the CFO was saying, was that they were willing to risk taking on more
debt, and become more highly geared in order for them to create value for their
shareholders. By increasing their debt capital, their equity capital would
reduce. This would surely increase the risk, given they are willing to be more
highly geared, or would it?
It is important
to also consider the other motives towards the move, as they wanted to use
their merger with AstraZeneca to move its tax base to the UK, a move commonly
known as tax inversion (Kollewe, 2014).
Well if Pfizer
were to increase their financial leverage, they risk exposing themselves to
risks and financial distress costs, and increase debt means increased repayment
costs (Petty et al, 2011). Pfizer currently have a debt to equity ratio (as of
2014) of around 0.50, as they have almost twice as much owner equity compared
to their debt (Stock Analysis on Net, 2014). So they are not currently at major
risk of increased debt, and could afford to take on more debt to boost their
balance sheet.
Frank D’Amelio
(CEO) had clear intentions of boosting shareholder wealth significantly through
the attempted takeover, and signalled that they were in a strong financial
position, despite decreasing profits, to take on more debt if it led to
increased shareholder wealth. However following the failed takeover, their
share price declined by 1 percent. This is not unusual, as even if the takeover
was approved Pfizer, as the bigger of the two, would have inevitably seen a
slight decrease in share price. However, if the deal was successful, then the
future share price would surely increase as the company was expanding its portfolio
with another major firm and would reap the benefits of M & A activity.
Of course,
there are tax reasons to why they wanted to acquire AstraZeneca, but they have
done so with the clear, stated, intention of increasing their shareholder
wealth by stating that they would be willing to take on more debt to make a
deal surface, with little risk to the company.
Reference
List
Kollewe, J. (2014). Pfizer unlikely to try AstraZeneca takeover again after tax clampdown. Retrieved from: http://www.theguardian.com/business/2014/nov/06/pfizer-unlikely-astrazeneca-takeover-tax-inversion-clampdown
Pettypiece, S.
(2014). Price the Reason
Pfizer-AstraZeneca Deal Died, CFO Says. Retrieved from: http://www.bloomberg.com/news/articles/2014-06-11/pfizer-cfo-says-astrazeneca-deal-broke-down-over-price